BioInvent International (BINV) Status Update summary

Recent business developments

• Announced a SEK 30 million deal with Exoma Royalties, including SEK 20 million upfront and SEK 10 million upon milestone approval for a second indication, monetizing a legacy asset to fund core programs.

• Exoma Royalties agreement is linked to a cross-license from 2003, with the milestone payment triggered by approval of a second indication in a phase 3 program.

Clinical program updates

• Lead programs BI-1206 and BI-1808 showed strong phase 2a data, with BI-1206 in combination therapy for non-Hodgkin's lymphoma demonstrating high response rates and good safety.

• BI-1808, a first-in-class drug for cutaneous T-cell lymphoma, showed impressive responses in advanced patients and received both Fast Track and orphan drug designations, expediting development and market protection.

• BI-1910 is advancing to phase 2a, and BI-1607 will have its first data set by year-end.

Strategic outlook and upcoming milestones

• Multiple clinical updates expected in the second half of the year, including further data for BI-1808 (as monotherapy and in combination with pembrolizumab), BI-1206 (in solid cancers), and BI-1910.

• Ongoing recruitment and dose optimization for BI-1808, with plans to expand BI-1206 studies into lung cancer and melanoma, aiming for earlier-stage interventions.

• The broad and unique portfolio positions the company for significant inflection points in the coming year.